#United States #Burlingame, California #Lilly TuneLab #Collaborative Drug Discovery #AI/ML Models

Collaborative Drug Discovery Partners with Lilly TuneLab

Collaborative Drug Discovery (CDD) has announced an exciting partnership with Eli Lilly and Company designed to revolutionize drug discovery processes. The collaboration focuses on integrating Lilly TuneLab, a state-of-the-art artificial intelligence and machine learning platform, into CDD Vault, CDD's flagship data management solution for the pharmaceutical and biotechnology industries.

Lilly TuneLab aims to accelerate biotech innovation by providing participating companies with access to models trained on a wealth of proprietary research data accumulated by Lilly over decades. This access allows biotech firms utilizing CDD Vault to tap into Lilly’s predictive models seamlessly within their existing research workflows.

Barry A. Bunin, the CEO and President of CDD, emphasized the importance of collaboration in overcoming complex challenges in drug discovery. He stated, “We believe that solving the most complex challenges in drug discovery will depend on innovative collaboration models that provide broad access to research data and empower chemists and biologists to make informed, data-driven decisions.” This vision aligns perfectly with CDD Vault’s capacity to facilitate collaborative research and streamline the drug development process.

The integration of TuneLab’s ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) models into the CDD Vault ecosystem is set to significantly enhance the capabilities of experimental and computational scientists. The advanced tools and environment of CDD Vault ensure that researchers can work with high-quality data securely and effectively.

Dr. Peter Gedeck, a Senior Scientist in CDD Research Informatics, pointed out that the partnership builds on CDD's foundational vision since its inception in 2004, showcasing the effectiveness of web-based collaboration. He also mentioned that “TuneLab's models are synergistic with our innovations such as Zero Click Models and Ultrafast Deep Learning similarity to SureChEMBL,” which makes adopting new models easier for users.

With CDD Vault already offering a variety of modules—ranging from chemical and biological registration management to structure-activity relationships—integrating Lilly's advanced predictive models will further enhance the platform's functionality. This evolution marks a significant milestone for both CDD and Lilly, setting a precedent for future collaborations in the sector.

To ensure a smooth integration process, the collaboration will include plans for integrating Lilly TuneLab within both the core and AI modules of CDD Vault for biotech companies that opt into this new initiative. As a result, researchers can seamlessly integrate advanced AI/ML-driven models into their daily operations, which is expected to expedite and improve decision-making in drug discovery.

In summary, this partnership between Collaborative Drug Discovery and Eli Lilly is a groundbreaking step toward integrating advanced AI technologies into real-world drug discovery workflows. As this initiative unfolds, it promises to set a new standard within the biotech landscape, fostering innovation and driving efficiencies that can lead to the development of new therapeutic solutions for complex health challenges.

For more information about this collaboration and CDD Vault, visit Collaborative Drug Discovery’s official website.